Overview

Exenatide Versus Glimepiride in Patients With Type 2 Diabetes

Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This study assesses the effects of twice-daily subcutaneous injection exenatide versus treatment with sulfonylurea (glimepiride) on long-term glycemic control and beta-cell function.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Eli Lilly and Company
Treatments:
Exenatide
Glimepiride